经口机器人手术对比根治性放化疗治疗口咽鳞状细胞癌的系统综述与Meta分析
该系统综述与Meta分析纳入15项研究共6767例口咽鳞状细胞癌患者,比较经口机器人手术(TORS)与根治性放疗或放化疗的疗效。结果显示TORS组总生存显著优于放疗/放化疗组(HR 0.51),但HPV阳性病例中无此差异;吞咽功能评分两组无显著差异,但放疗/放化疗组较基线下降幅度更大。
要点
- TORS组总生存显著优于根治性放疗/放化疗组(HR 0.51,95%CI 0.42-0.62)。
- HPV阳性病例中TORS与放疗/放化疗的总生存无显著差异。
- 两组吞咽功能评分无显著差异,但放疗/放化疗组较基线下降幅度近两倍。
核心结论
- TORS联合或不联合辅助治疗与根治性放疗/放化疗相比,与更高的总生存相关。
- TORS与较基线更小的功能结局下降相关。
- 鉴于多数研究为非随机设计,结果需谨慎解读。
研究设计与样本
- 系统检索PubMed、Scopus和Embase,按PRISMA指南筛选相关研究。
- 采用随机效应模型比较TORS与初始放疗或放化疗的总生存、疾病特异性生存和吞咽功能。
- 共纳入15项研究,6767例患者,其中2423例接受TORS,4344例接受初始放疗或放化疗。
主要发现
- TORS组总生存显著优于放疗/放化疗组(HR 0.51;95% CI 0.42-0.62;p < 0.0001),在所有疾病分期中均如此,但HPV阳性病例中无显著差异。
- 无进展生存两组无显著差异(HR 0.81;95% CI 0.50-1.29;p = 0.374)。
- MDADI和FOIS评分两组无显著差异(MD 0.8;95% CI -2, -3.5;p = 0.578;和MD 0.2;95% CI -0.3, -0.7;p = 0.469)。
- 与基线相比,两组MDADI评分均下降,但放疗/放化疗组下降幅度近两倍(MD 3.5;95% CI 3.1-3.9;p < 0.001)。
临床怎么用
- 对于口咽鳞状细胞癌患者,TORS可作为与根治性放疗/放化疗相比总生存更优的治疗选择,但需结合HPV状态个体化决策。
- TORS可能有助于减少吞咽功能较基线的下降,但需注意多数证据来自非随机研究。
局限性
- 多数纳入研究为非随机设计,结果需谨慎解读。
- 需未来研究确定口咽鳞状细胞癌的最佳治疗策略及HPV状态对治疗选择的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trans-oral robotic surgery is a minimally invasive surgical approach for the treatment of oropharyngeal squamous cell carcinoma (OPSCC), with superior functional outcomes compared to open surgery. However, its oncologic and functional outcomes are still debated in comparison to definitive radiotherapy (RT) or chemoradiotherapy (CRT). METHODS: A systematic search was conducted in PubMed, Scopus, and Embase, and relevant studies were selected in accordance with the PRISMA guidelines. Overall survival, disease-specific survival, and swallowing function are compared between TORS and primary RT or CRT using random-effects models. Dysphagia was assessed using the MD Anderson Dysphagia Index (MDADI) and the Functional Oral Intake Scale (FOIS). RESULTS: A total of 15 studies comprising 6767 patients (2423 underwent TORS and 4344 underwent upfront RT or CRT) were included. Overall survival was significantly better after TORS (HR 0.51; 95% CI 0.42-0.62; p < 0.0001), in all stages of disease, but not in HPV-positive cases. No significant difference was found in progression-free survival (HR 0.81; 95% CI 0.50-1.29; p = 0.374). MDADI and FOIS scores were not significantly different among the two groups (MD 0.8; 95% CI -2, -3.5; p = 0.578; and MD 0.2; 95% CI -0.3, -0.7; p = 0.469; respectively). Compared to baseline, MDADI scores were decreased in both groups; but the decline was almost two-fold larger in the RT/CRT group (MD 3.5; 95% CI 3.1-3.9; p < 0.001). CONCLUSIONS: TORS with or without adjuvant treatment was associated with higher overall survival compared to definitive RT/CRT. TORS was also associated with less decline in functional outcomes compared to baseline. Considering the non-randomized nature of most available studies, these results should be interpreted with caution. Future studies are warranted to determine the optimal treatment strategies for patients with OPSCC and to investigate the implications of HPV status on treatment selection.
引用
- Zamani R, Ohadi MAD, Pouremamali R, et al. Transoral Robotic Surgery-Based Treatment Versus Definitive Chemoradiation for Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Head Neck. 2026. PMID: 42087273. doi:10.1002/hed.70308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。